Maspin staining in TCC. (A) A strong Maspin protein expression with cytoplasmic and nuclear staining in non-recurrent and non-progressive pTa tumor. (B) Faint Maspin protein expression without nuclear staining in a progressive pTa tumor. 

Maspin staining in TCC. (A) A strong Maspin protein expression with cytoplasmic and nuclear staining in non-recurrent and non-progressive pTa tumor. (B) Faint Maspin protein expression without nuclear staining in a progressive pTa tumor. 

Source publication
Article
Full-text available
Maspin is a 42-kDa protein that belongs to the family of serine protease inhibitors. It is involved in various physiological processes. In cancer tissue, Maspin was found to influence angiogenesis, tumor growth, metastasis and the prognosis of tumor patients. This study was performed to analyze the involvement of Maspin in transitional cell carcino...

Context in source publication

Context 1
... of 3 years. In case of tumor recurrence or progression, tumor specimens were included regardless of the time when either recurrence or progression occurred. Recurrence was defined as the reap - pearance of tumors of the same stage. Progression was defined as tumor development from non-muscle to muscle invasive disease. For classification, the tumor, node and metastasis (TNM) staging system was used. The tumors were initially graded by pathologists according to the 1973 World Helath Organization grading system (18). Tumor specimens were fixed in formalin, dehydrated and embedded in paraffin. The paraffin blocks were cut into 4-μm sections. Hematoxylin and eosin staining was performed for each tumor specimen to validate tumor stage and grade. Tissue microarrays (TMAs) were constructed and stained as previously described (17,19-21). A commercially available Maspin antibody (monoclonal mouse antibody; NCL-Maspin, Novocastra Laboratories Ltd.) in a dilution of 1:500 was used. For the negative control, the primary anti-human Maspin anti- body was replaced by non-immune mouse serum. The TMA slides were reviewed and classified by two independent investigators (M.W.K. and A.S.M) in a blinded manner. For statistical analysis, the immunohistochemical staining reaction was classified according to a semiquantita - tive reference scale ranging from ʻ0̓ to ʻ3+̓, depending on the intensity of the Maspin protein expression. The rela- tive amount of tumor cells stained positively for Maspin (0-100%) in conjunction with the rating of the staining inten- sity, resulted in a staining score ranging from 0 to 300 as previously described (19). The same evaluation method was validated in previous studies (17,21). The concordance rate of the investigators was 90%. Statistical analysis. The JMP program was used for statis- tical evaluations. A D’Augostino and Pearson omnibus normality test was performed to determine whether all data sets were parametric or non-parametric. One-way ANOVA and the Student's t-test were applied to correlate the Maspin expression with various tumor characteristics. Time-to-event probabilities were estimated by the univariate Kaplan-Meier method. The Cox proportional hazard model was applied for the multivariate analysis. P<0.05 was considered to indicate statistically significant differences. Clinicopathological data. Specimens of 162 patients [119 (73%) male and 43 (27%) female] with non-muscle invasive TCC as detected using cystoscopy were included in the present study. Tumor stages according to the TNM system were determined as follows: pTa, n=91 (56%) and pT1, n=71 (44%). Since exclusively non-muscle invasive tumors were investigated, no information on lymph node invasion and distant metastasis was recorded. Of the 162 specimens, 59 (36%) were graded as G1, 90 (56%) as G2 and 13 (8%) as G3. Follow-up data were available for patients with a median follow-up of 58.5 months. Tumor recurrence was observed in 84 (52%) patients, and tumor progression in 28 (17%) patients. The average time interval between initial treatment and time of recurrence was 14 (3-72) and 23 (3-79) months for tumor progression (Table I). Maspin expression. Maspin protein was detected in the nucleus and cytoplasm of the TCC specimens. A clear shift from high to faint staining within the nucleus was observed with more aggressive forms of non-muscle invasive TCC specimens in terms of risk of recurrence and progression. In 12 muscle-invasive tumor tissues used as comparative samples, no nuclear staining was observed (unpublished data). Statistical analysis of Maspin protein expression in the TMAs is shown in Table II. Urothelium-defined (pTa) and minimally invasive TCC (pT1) were not distinguished by immunohistochemically detected Maspin protein expression (p=0.42). TCCs with low and high tumor grades (G1 and G3) showed a lower Maspin expression compared to grade 2 tumors. CIS was noted in 8 patients. While the presence of CIS correlated with Maspin staining scores (p<0.05), multi - focal tumors at the time of diagnosis showed no significant correlation (p=0.41). We evaluated whether the Maspin protein expression in non- muscle invasive bladder cancer specimens predicts tumor recurrence and/or muscle invasion. Results are shown in Table II. Table II. Decreased staining levels in pTa, as well as in combi- nation with pT1 tumors showed a higher incidence of tumor relapse (p<0.05, Student's t-test) as confirmed by Chi-square analyses (Table II, Fig. 1). However, the Kaplan-Meier analysis did not indicate any significant prognostic value in respect to tumor recurrence. As shown in Table III, sensitivity and speci- ficity were low, at 52 and 67%, respectively. The univariate analysis of the prognostic significance of the staining score in relation to the likelihood of tumor progression showed that a strong Maspin expression and nuclear staining were associated with better survival in terms of tumor progression (Table II, (Table II, Fig. Fig. 3). Significant lower staining scores were noted in pTa and pT1 tumors and a reduction in nuclear staining in tissue samples of patients who showed tumor progression within the follow-up time period (p<0.001; Student's t-test). Subsequently, a Kaplan-Meier analysis was performed to further stratify the prognostic value of Maspin. Therefore, we classified the analyzed cohort into groups (A vs. B) according to a receiver operating curve. The cut-off limit (Group A ≥ 175 vs. B < 175) was based on the highest area under the curve and selected using the JMP statistical program (JMP 6 software, SAS Institute, Cary, NC, USA). Sensitivity and specificity were then calculated as 95 and 70%, respectively (Table III). As illustrated in Fig. 2, low Maspin protein expression levels were highly associated with a shorter progression-free survival (46 vs. 18 months; p<0.0001, Log-rank test). To determine which of the studied parameters and/or Maspin staining are independent prognostic indicators of tumor progression to muscle invasion, we used the Cox proportional hazard model. The statistical analysis affirmed only Maspin as an indepen - dent prognostic predictor for the likelihood of progression (p<0.0001; Table II). Further parameters, such as tumor stage and grade, presence of concomitant CIS, multifocality, age and gender, were included. None of these parameters were statistically significant. Maspin is a 42-kDa protein associated with various tumor- related processes such as the inhibition of cell migration, cell invasion, angiogenesis, as well as improvement in cell adhesion and the induction of programmed cell death, thus classifying it as a tumor suppressor (8-12). Maspin expression has been observed in multiple tissues, e.g., epithelium of the breast, prostate, epidermis and lung (10,22-24). Localization within the cell appears to define its function. Loss of nuclear expression in ovarian, breast and lung cancer coincides with more aggressive phenotypes and decreased survival (25-27). We found a shift from nuclear to a predominantly cytoplasmic staining in 12 muscle-invasive tissue samples and, notably, in highly aggressive forms of non-muscle invasive bladder cancer. Tissues from patients that showed progression to muscle-invasive disease detected by subsequent cytoscopies following initial diagnosis showed less nuclear staining in the primary tissue. This observation stresses the assumption that cytoplasmic Maspin in the early steps of tumor progres- sion may signal an imperfect suppressive effect. Currently, only four studies evaluating Maspin expression in bladder cancer have been published. Of these, only Blandamura et al described the possible role of nuclear vs. cytoplasmic staining (16). These authors found a correlation between nuclear Maspin expression and lower histological grades (PUNLMP and low grade). This stresses the prognostic value of Maspin since low-grade and PUNLMP tumors are less likely to progress to muscle-invasive tumor stages (pT≥2). By exclusively including pTa and pT1 tissues in this inves- tigation, we were unable to show significance in respect to tumor stage and grade of the 162 examined samples. Similar results were published by Friedrich et al who found a predom- inantly weak Maspin protein expression in pTa and pT1 tumors without any correlation in respect to stage and grade (15). The two studies must be analyzed in contrast to that of Blandamura and colleagues who reported a statistical associa- tion between the Maspin staining pattern and stage and grade. It appears that a strong Maspin expression was associated with high-grade tumors whereas low-grade tumors and PUNLMP expressed less Maspin (16). When comparing Maspin protein expression in non-muscle invasive to muscle-invasive bladder cancer, Sugimoto et al were the first to describe an increased expression in higher tumor stages (pT≥2 > pTa/pT1) (14). However, in concordance to our results, no statistical differ - ence was found when comparing pTa and pT1 tumors as 23 of the 27 specimens showed no Maspin expression at any rate. Following loss of the Maspin protein expression in muscle-invasive tumor samples which suggested prognostic significance, Beecken and colleagues further examined Maspin mRNA expression in different bladder cell lines (13). Highly aggressive tumor cell lines (MGHU1, UMUC3) showed no Maspin mRNA expression. A subsequent investigation of the in vivo tumor growth rate found a close inverse correlation to the Maspin expression, highly emphasizing its prognostic value. However, apart from the previous promising results, no statistically significant correlation between Maspin staining and tumor relapse of pTa tumors was observed. Notably, the cohort of 24 patients for follow-up information in that study was small. In the present study, follow-up information was collected from 162 patients with a minimum follow-up time of 36 months (median 58.5). A Chi-square analysis indicated Maspin to be a ...

Citations

... MCM2 belongs to the MCM family and has been identified as a biomarker for the progression and prognosis of several types of human cancers (24). MCM2 is highly expressed in a variety of human cancers, including breast cancer, stomach cancer, colorectal cancer, lung cancer, and hepatocellular carcinoma (25)(26)(27)(28)(29)(30)(31). Wu et al. reported that the expression level of MCM2 was upregulated in LUSC tissues and cell lines, and that MCM2 was related to the low overall survival of LUSC patients (32). ...
... SERPINB5, a member of the serpin superfamily, is a serine protease inhibitor that suppresses tumor progression and metastasis (33)(34)(35). Higher SERPINB5 expressions have been reported to be associated with better prognosis in non-small cell lung cancer, esophageal squamous cell carcinoma, ovarian cancer, and bladder cancer (25)(26)(27)36). In the present study, SERPINB5 expression was increased in LUSC tissues compared with normal tissues. ...
Article
Full-text available
Background: The aim of the present study was to find diagnostic and prognostic biomarkers for lung squamous cell carcinoma (LUSC) and to validate key biomarkers in vitro. Methods: RNA sequencing was used to identify differentially expressed mRNAs (DEmRNAs) and differentially expressed long non-coding RNAs (DElncRNAs) in LUSC tissues. RNA sequencing results were validated using a published dataset. Diagnostic and prognostic values of candidate genes were evaluated by receiver-operating characteristic (ROC) curve analysis and survival analysis, respectively. To determine the effect of MIR205HG in LUSC, MIR205HG expression was knocked down in NCI-H520 cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and Transwell assay were used to respectively detect the effect of MIR205HG on cell proliferation and migration. Results: In total, 1,946 DEmRNAs and 428 DElncRNAs were identified in LUSC compared with normal tissues. A total of 851 DElncRNA-DEmRNA co-expression pairs were obtained. With the exception of NEAT1, MCM2, SERPINB5, ITGB8, CASC19, and MIR205HG were upregulated in LUSC. ROC curve analysis indicated that MCM2, SERPINB5, ITGB8, CASC19, and MIR205HG could predict LUSC. Survival analysis suggested that SERPINB5, NEAT1, and MIR205HG had potential prognostic value for LUSC. MIR205HG knockdown inhibited cell proliferation and migration, and significantly reduced the expression of ITGB8. Conclusions: The findings of the present study could help determine the pathogenesis of LUSC and provide new and accurate therapeutic targets for its treatment.
... Maspin is a protein of the family of serine protease inhibitors that participates in angiogenesis and metastasis in tumor tissues; in a study with 162 patients with stages pTa-T1 NMIBC, maspin expression predicted progression with a sensitivity of 95% and a specificity of 70% (p <0.001); and recurrence, with a sensitivity of 52% and specificity of 67% (p <0.05) (66). ...
Article
Full-text available
Purpose: Proteomic biomarkers have been emerging as alternative methods to the gold standard procedures of cystoscopy and urine cytology in the diagnosis and surveillance of bladder cancer (BC). This review aims to update the state of the art of proteomics research and diagnosis in BC. Materials and methods: We reviewed the current literature related to BC research on urinary, tissue, blood and cell line proteomics, using the Pubmed database. Findings: Two urinary protein biomarkers are FDA-approved (NMP22® and BTA® tests), only if performed along with cystoscopy for surveillance after initial diagnosis, but not in the primary diagnostic setting due to high false-positive rates in case of infections, stones and hematuria. There are a great number of non-FDA approved proteins being studied, with good preliminary results; panels of proteins seem valuable tools to be refined in ongoing trials. Blood proteins are a bigger challenge, because of the complexity of the serum protein profile and the scarcity of blood proteomic studies in BC. Previous studies with the BC tissue proteome do not correlate well with the urinary proteome, likely due to the tumor heterogeneity. Cell line proteomic research helps in the understanding of basic mechanisms that drive BC development and progression; the main difficulty is culturing low-grade tumors in vitro, which represents the majority of BC tumors in clinical practice. Conclusion: Protein biomarkers have promising value in the diagnosis, surveillance and prognostic of BC. Urine is the most appropriate body fluid for biomarker research in BC due to its easiness of sampling, stability and enrichment of shed and secreted tumor-specific proteins. Panels of biomarkers may exhibit higher sensitivity than single proteins in the diagnosis of BC at larger populations due to clinical and tumor heterogeneity. Prospective clinical trials are warranted to validate the relevance of proteomic data in the clinical management of BC.
... However, controversial studies concerning the expression and function of maspin in bladder cancer have been conducted. Some studies have indicated that maspin expression can play a possible clinical role as a novel tumor suppressor gene in the bladder's transitional cell carcinoma and can be a useful prognostic marker for predicting the tumor behavior in stage T1 bladder tumors [7,8]. Strong expression of maspin was observed in normal urothelium, and the expression of maspin significantly decreased in invasive carcinoma. ...
... IHC staining in human bladder tissue arrays also revealed that normal bladder tissues expressed significantly higher maspin protein levels than bladder cancerous tissues (Figure 1). These results indicated that maspin can be regarded as an antitumor gene in bladder cancer, which is in agreement with previous studies from several independent laboratories [7][8][9]20,21]. However, our in vitro study results revealed that TSGH-8301 cells expressed the highest maspin protein levels among the four carcinoma cell lines (RT-4, HT1376, T24, and TSGH-8301), which indicated that maspin expression among the bladder carcinoma cell lines is dependent on the cell type but is not related to the extent of neoplasia in vitro. ...
Article
Full-text available
Maspin is a member of the clade B serine protease inhibitor superfamily and exhibits diverse regulatory effects in various types of solid tumors. We compared the expressions of maspin and determined its potential biological functions and regulatory mechanisms in bladder carcinoma cells in vitro and in vivo. The results of RT-qPCR indicated that maspin expressed significantly lower levels in the bladder cancer tissues than in the paired normal tissues. The immunohistochemical assays of human bladder tissue arrays revealed similar results. Maspin-knockdown enhanced cell invasion whereas the overexpression of maspin resulted in the opposite process taking place. Knockdown of maspin also enhanced tumorigenesis in vivo and downregulated protein levels of acetyl-histone H3. Moreover, in bladder carcinoma cells, maspin modulated HDAC1 target genes, including cyclin D1, p21, MMP9, and vimentin. Treatment with MK2206, which is an Akt inhibitor, upregulated maspin expression, whereas PTEN-knockdown or PTEN activity inhibitor (VO-OHpic) treatments demonstrated reverse results. The ectopic overexpression of p53 or camptothecin treatment induced maspin expression. Our study indicated that maspin is a PTEN-upregulated and p53-upregulated gene that blocks cell growth in vitro and in vivo, and may act as an HDAC1 inhibitor in bladder carcinoma cells. We consider that maspin is a potential tumor suppressor gene in bladder cancer.
... These techniques do not allow a high-throughput screen- ing and are relatively time-consuming. 7,24 In our study, we have used more sensitive and quantitative assay, ELISA, for the measurement of Inspite of recent advancement, poor prognosis remains one of the distressing features of GBC. 25 Newer prognostic markers are needed for the management of this lethal malignancy. Prognostic significance of MASPIN gene in GBC has hardly been studied. ...
... Follow-up conforming to the guidelines was recommended to all referring urologists, who performed followups themselves, but data about the reliability of the recommended follow-up is lacking. The same cohort was validated in four previous biomarker studies investigating galectin-3 [17], HYAL-1 hyaluronidase [18], maspin [19], and galectin-8 [20]. Recurrence was defined as the reappearance of a tumor at the same tumor stage. ...
Article
Full-text available
Introduction There is an urgent need to identify patients with bladder cancer (BC) who are at high risk of recurrence or progression. Calgranulin A is a strong marker for muscle-invasive or advanced BC and recent studies have shown its potential for identifying patients at risk even in non-muscle-invasive bladder cancer (NMIBC). The present study examines risks of recurrence and progression dependent on immunostaining with calgranulin A in NMIBC. Methods Calgranulin A protein expression was evaluated through the immunohistochemistry of 158 randomly selected, transurethrally resected BC specimens of separate patients (pTa 89, pT1 69) using tissue microarrays. Kaplan–Meier survival analysis and Cox regression were performed to determine whether calgranulin A expression is associated with recurrence-free survival (RFS), progression-free survival (PFS), or cancer-specific survival (CSS). Results Calgranulin A expression is significantly different between pTa and pT1 tumors (p = 0.000, Mann–Whitney U test) and between tumor grades (p = 0.015, Kruskal–Wallis test). Kaplan–Meier estimates produced significant results for low and high calgranulin A expression concerning RFS [5y-RFS 70.4 ± 4.0% vs. 35.9 ± 12.5%, median RFS not reached (NR) vs. 12.0 ± 4.4 month, p = 0.029, log-rank test], PFS (5y-PFS 90.3 ± 2.7% vs. 51.5 ± 14.0%, median PFS NR in both groups, p = 0.000, log-rank test), and CSS (5y-CSS 92.9 ± 2.6% vs. 70.7 ± 12.4%, median CSS NR in both groups, p = 0.005, log-rank test). Calgranulin A remained an independent factor for RFS (p = 0.024, HR 2.43) and PFS (p = 0.002, HR 5.92) according to the multivariate Cox regression model. Conclusions Calgranulin A expression in NMIBC, detected through immunohistochemistry, is a promising marker for the identification of NMIBC patients at high risk of recurrence and progression.
... SERPINB5-transfected breast cancer cells also showed reduced abilities for invasion and metastasis in vitro and in vivo, respectively. Expression of SERPINB5 was also associated with a better prognosis in prostate cancer [35], bladder cancer [36,37], non-small cell lung cancer [38,39] and ovarian cancer [40]. However, SERPINB5 was overexpressed in pancreatic [41], gallbladder [42], thyroid [43], as well as colorectal cancers [44]. ...
Article
Full-text available
Background: Due to the varying characteristics and conflicting outcomes on the overall survival of rectal cancer patients, many studies have been undertaken to determine various prognostic and predictive factors for the mainstay treatment of CCRT followed by surgery. Cancer cell motility contributes to tumor invasion, migration and eventually metastasis. However, the genes associated with cell motility (i.e., GO:0048870) have not been systemically evaluated in rectal cancers. Methods: A comparative analysis of gene expression profiles was applied to the transcriptomic dataset (GSE35452) with a focus on genes associated with cell motility (GO:0048870), where SERPINB5 was recognized as the most significantly up-regulated gene. Tumor samples from 172 primary rectal cancer patients who underwent neoadjuvant CCRT followed by surgical resection were collected. Immunohistochemistry was used to semi-quantitatively assess the expression level of SERPINB5 protein. Statistical analyses of SERPINB5 expression and various clinicopathological features as well as survival were then performed. Results: High immunoreactivity of SERPINB5 was significantly linked to pre- and post-CCRT advanced disease, lymphovascular invasion, and poor response to CCRT (all P ≤ 0.015). SERPINB5 overexpression was not only negatively associated with disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS) rates in univariate analyses but also was an independent prognostic factor for DSS and MeFS in rectal cancer patients (all P ≤ 0.043). Conclusion: SERPINB5 may play an important role in rectal cancer progression and response to neoadjuvant CCRT and serve as a novel prognostic factor.
... Emerging evidence shows that Maspin expression was preserved in superficial bladder cancers and its expression associated with good prognosis. Kramer [18] investigated specimens from 162 non-muscle invasive bladder cancer patients treated by transurethral resection. They showed positive Maspin expression rate was 75.9 % and had a longer PFS compared with negative expression (46 vs 18 months, respectively). ...
Article
Full-text available
Background Maspin, a non-inhibitory member of the serine protease inhibitor superfamily, has been characterized as a tumor suppressor gene in multiple cancer types. Chemotherapeutic insensitivity is one of major obstacles to effectively treating muscle invasive bladder cancer (MIBC). This study was conducted to investigate the role and probable mechanism of Maspin enhancing cisplatin chemosensitivity of bladder cancer in vitro and MIBC patients. Methods Maspin expression was quantified by qRT-PCR in two MIBC cell lines (T24 and 5637). After successful established Maspin overexpression model by lipidosome transfection, MTT and cell apoptosis assay were used to assess the MIBC’s cisplatin sensitivity. Western blot method was used to test PI3K/ AKT/mTOR signal passway and apoptosis related molecules Caspase3 and Bcl-2. Additionally, we evaluated Maspin expression and prognosis in 62 MIBC cases who underwent cisplatin based neoadjuvant chemotherapy (NACT) using immunohistochemistry. Result Upregulate Maspin expression could enhance the chemosensitivity induced by cisplatin in T24 and 5637 cell lines. The cell viability, cloning ability and IC50 were reduced while apoptosis rate was upregulated when cells were transfected Maspin. Phospho(p)-AKT, PI3K, mTOR, and Bcl-2 expression were significantly decreased, whereas Caspase3 was greatly increased in the Maspin group. In the clinic study, there was significant correlation between Maspin expression and overall survival (OS) and progression-free survival (PFS) rate in MIBC patients who received cisplatin based NACT. Conclusion Maspin could enhance cisplatin chemosensitivity in T24 and 5637 cell lines. Its expression correlated with prognosis of MIBC patients who received cisplatin based neoadjuvant chemotherapy.
... Not surprisingly, shorter progression-free survival rates are seen in tumors that are negative for maspin. These results have been corroborated by Kramer et al. [5] in a recent study. ...
... Specimens from 162 nonmuscle invasive bladder cancer patients treated by transurethral resection were examined. They showed that a low maspin protein expression was correlated with a higher incidence of tumor progression and emphasized a possible clinical role of this novel tumor suppressor gene in transitional cell carcinoma of the bladder [81]. ...
Article
Full-text available
Maspin (mammary serine protease inhibitor), is a member of the serine protease inhibitor/non-inhibitor superfamily. Its expression is down-regulated in breast, prostate, gastric and melanoma cancers but over-expressed in pancreatic, gallbladder, colorectal, and thyroid cancers suggesting that maspin may play different activities in different cell types. However, maspin expression seems to be correlated with better prognosis in prostate, bladder, lung, gastric, colorectal, head and neck, thyroid and melanoma cancer. In breast and ovarian cancer maspin significance is associated with its subcellular localization: nucleus maspin expression correlates with a good prognosis, whilst in pancreatic cancer it predicts a poor prognosis. Since tumor metastasis requires the detachment and invasion of tumor cells through the basement membrane and stroma, a selectively increased adhesion by the presence of maspin may contribute to the inhibition of tumor metastasis. Furthermore the different position of maspin inside the cell or its epigenetic modifications may explain the different behavior of the expression of maspin between tumors. The expression of maspin might be useful as a prognostic and possibly predictive factor for patients with particular types of cancer and data can guide physicians in selecting therapy. Its expression in circulating tumor cells especially in breast cancer, could be also useful in clinical practice along with other factors, such as age, comorbidities, blood examinations in order to select the best therapy to be carried out. Focusing on the malignancies in which maspin showed a positive prognostic value, therapeutic approaches studied so far aimed to re-activate a dormant tumor suppressor gene by designed transcription factors, to hit the system that inhibits the expression of maspin, to identify natural substances that can determine the activation and the expression of maspin or possible “molecules binds” to introduce maspin in cancer cell and gene therapy capable of up-regulating the maspin in an attempt to reduce primarily the risk of metastasis. Further studies in these directions are necessary to better define the therapeutic implication of maspin.